Document is current
Any future updates will be listed below
-
Authors
Fares-Otero, Natalia E. https://orcid.org/0000-0002-8589-7384
Iversen, Astrid E. https://orcid.org/0009-0000-5484-8945
Gutiérrez-Zotes, Alfonso
Zarp, Jeff https://orcid.org/0000-0002-3415-8098
Jiménez, Esther
Sánchez-Moreno, Jose https://orcid.org/0000-0003-1520-093X
Pomarol-Clotet, Edith
Vieta, Eduard https://orcid.org/0000-0002-0548-0053
Kjærstad, Hanne L. https://orcid.org/0000-0001-7781-8853
Vilella, Elisabet https://orcid.org/0000-0002-1887-5919
Miskowiak, Kamilla W. https://orcid.org/0000-0003-2572-1384
- License Information
-
More Information
Article History
Received: 7 November 2025
Revised: 14 May 2026
Accepted: 12 June 2026
First Online: 20 June 2026
Competing interests
: JZ has received honoraria from Lundbeck Pharma A/S within the past three years. HLK has received honoraria from Lundbeck within the last three years. Eduard Vieta has received grants and served as a consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Angelini, BeckleyPsych, Biogen, Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Janssen, Lundbeck, Luye Pharma, Medincell, Merck, Newron, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatris, outside of the submitted work. KWM has received honoraria from Lundbeck, Angelini and Gedeon Richter in the past three years. The other authors report no financial relationships with commercial interests.
